Novartis using Emisphere technology in tests

June

Emisphere Technologies Inc., the biopharmaceutical company with research and development operations in Eastview, said this morning that Novartis Pharma AG has launched a study to determine whether a drug is effective in treating osteoporosis in women who are past menopause. Novartis will test oral PTH134 using Emisphereâ€™s Eligen technology. The testing is being done in Switzerland.

This entry was posted on Monday, June 30th, 2008 at 9:31 am by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.